Novo Nordisk filing move brings Tresiba closer to U.S. market

March 26, 2015 5:36 PM

16 0

(Reuters) - Denmark's Novo Nordisk said on Thursday it had decided to submit interim analysis data from a clinical trial of its crucial new insulin drug Tresiba to U.S. regulators within the next month.

The decision is likely to be a relief to investors, since a decision not to file on Tresiba and the related drug Ryzodeg would have further delayed a launch in the world's biggest market.

Read more

To category page